BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

As disruptions begin to mount among biopharmas’ planned or ongoing clinical trials during the COVID-19 outbreak, newly issued FDA guidance clarified the agency’s thinking on how sponsors can ensure participants’ safety and implement modifications to...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BC Innovations | Oct 3, 2018
Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture and rat studies identified a positive allosteric modulator (PAM) of mGluR4 that could help treat catalepsy in PD. Optimization and testing in human mGluR4-expressing CHO cells of a previously...
BC Innovations | Apr 3, 2018
Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest positive allosteric modulators (PAMs) of CHRM4 could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of CHRM4 were lower than...
BC Week In Review | Mar 30, 2018
Financial News

Addex raises $43M

Addex Therapeutics Ltd. (SIX:ADXN) raised CHF41 million ($43 million) on March 29 through the sale of 13 million shares at CHF3.13 to New Enterprise Associates, New Leaf Venture Partners, CAM Capital and clients of Semper...
BC Extra | Mar 29, 2018
Financial News

Addex raises $43M

Addex Therapeutics Ltd. (SIX:ADXN) raised CHF41 million ($43 million) Thursday through the sale of 13 million shares at CHF3.13 to New Enterprise Associates, New Leaf Venture Partners, CAM Capital and clients of Semper Finance Group...
BC Week In Review | Feb 23, 2018
Financial News

Addex proposes CHF40M private placement

Neurology company Addex Therapeutics Ltd. (SIX:ADXN) proposed on Feb. 15 to raise up to CHF40 million ($42.7 million) through the sale of 12.8 million shares at CHF3.43 in a private placement. The company said CHF30...
BC Extra | Feb 17, 2018
Financial News

Addex proposes CHF40M private placement

Addex Therapeutics Ltd. (SIX:ADXN) proposed Thursday to raise up to CHF40 million ($42.7 million) through the sale of 12.8 million shares at CHF3.43 in a private placement. The company said CHF30 million of the offering...
BC Extra | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
BC Innovations | Sep 14, 2017
Translation in Brief

Tracking TrkB agonists

It turns out that neurotrophic TrkB agonists used in many publications aren't TrkB agonists after all, according to a recent Science Signaling paper from Columbia University and the Broad Institute of MIT and Harvard . The...
Items per page:
1 - 10 of 228
BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

As disruptions begin to mount among biopharmas’ planned or ongoing clinical trials during the COVID-19 outbreak, newly issued FDA guidance clarified the agency’s thinking on how sponsors can ensure participants’ safety and implement modifications to...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

Two senior executives at Biogen Inc. (NASDAQ:BIIB) have stepped down this past week: EVP of Corporate Development Daniel Karp and Anirvan Ghosh, SVP, head of research and early development. Ghosh will become CEO of cellular...
BC Innovations | Oct 3, 2018
Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Cell culture and rat studies identified a positive allosteric modulator (PAM) of mGluR4 that could help treat catalepsy in PD. Optimization and testing in human mGluR4-expressing CHO cells of a previously...
BC Innovations | Apr 3, 2018
Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest positive allosteric modulators (PAMs) of CHRM4 could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of CHRM4 were lower than...
BC Week In Review | Mar 30, 2018
Financial News

Addex raises $43M

Addex Therapeutics Ltd. (SIX:ADXN) raised CHF41 million ($43 million) on March 29 through the sale of 13 million shares at CHF3.13 to New Enterprise Associates, New Leaf Venture Partners, CAM Capital and clients of Semper...
BC Extra | Mar 29, 2018
Financial News

Addex raises $43M

Addex Therapeutics Ltd. (SIX:ADXN) raised CHF41 million ($43 million) Thursday through the sale of 13 million shares at CHF3.13 to New Enterprise Associates, New Leaf Venture Partners, CAM Capital and clients of Semper Finance Group...
BC Week In Review | Feb 23, 2018
Financial News

Addex proposes CHF40M private placement

Neurology company Addex Therapeutics Ltd. (SIX:ADXN) proposed on Feb. 15 to raise up to CHF40 million ($42.7 million) through the sale of 12.8 million shares at CHF3.43 in a private placement. The company said CHF30...
BC Extra | Feb 17, 2018
Financial News

Addex proposes CHF40M private placement

Addex Therapeutics Ltd. (SIX:ADXN) proposed Thursday to raise up to CHF40 million ($42.7 million) through the sale of 12.8 million shares at CHF3.43 in a private placement. The company said CHF30 million of the offering...
BC Extra | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
BC Innovations | Sep 14, 2017
Translation in Brief

Tracking TrkB agonists

It turns out that neurotrophic TrkB agonists used in many publications aren't TrkB agonists after all, according to a recent Science Signaling paper from Columbia University and the Broad Institute of MIT and Harvard . The...
Items per page:
1 - 10 of 228